NYSDOH approval, widely recognized as the most rigorous state-level clinical laboratory regulatory standard in the U.S., further strengthens DELFI's regulatory pathway toward FDA in vitro diagnostic device approval PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of AI-powered, blood-based tests for cancer detection, today announced it has received a Clinical Laboratory Permit and Test Approval letter from the New York State Department of Health (NYSDOH). With

继续和 MRCLUB 的小伙伴们分享业界高管动态。 5 月 27 日晚，微创医疗科学有限公司对外宣布，格雷格·霍尔曼（Greg Holman）加入公司，担任首席商务官（CCO）。 据公告，加入之后，格雷格·霍尔曼负责集团国际业务的战略制定与执行，推进“One MicroPort”战略，将统筹海外地区的产品组合规划、品牌整合及市场拓展，重点推动全球通（GloMatrix）的发展和业务增长。 从履历来看，格雷格·霍尔曼（Greg Holman）是一位兼具跨国医疗器械企业管理、亚太市场商业化和中国本土运营经验的职业经理人。 加入微创之前，他曾在波士顿科学和史赛克等全球医疗科技公司担任高级管理职务，职业经历覆盖心血管、神经介入、骨科及医疗数字化等多个领域。 在史赛克期间，霍尔曼曾出任中国区总裁，深度参与史赛克在中国市场的业务拓展和本土化推进。此后，他转向医疗健康投资与运营赋能领域，担任 LYFE Capital 运营合伙人，参与医疗科技企业的商业化和组织发展支持。 对于正处在国际化加速阶段的微创医疗来说，霍尔曼的加入，意味着这家公司希望引入更成熟的全球医疗器械商业化经验，进一步整合海外产品组合

继续和 MRCLUB 的小伙伴们分享跨国药企动态。 这两年，如果要在全球医药行业找一个最受资本市场追捧的名字，礼来大概率绕不过去。 近日，礼来股价突破 1000 美元，公司市值再次站上 1 万亿美元关口，继续坐稳全球市值最高药企的位置。 我们来看一下，截至 2026 年 5 月 28 日盘中，礼来股价一度达到约 1145 美元，市值约 1.02 万亿美元。放在全球药企里面看，这依然是一个非常特殊的数字。因为到目前为止，在跨国药企中，礼来仍是历史上唯一市值突破过 1 万亿美元的公司。 这一次礼来再破万亿，表面看是股价再创新高，背后真正撑起来的，还是 GLP-1 带来的增长确定性。 从最新财报看，礼来的增长速度已经不像一家传统大型药企。 2026 年第一季度，礼来全球收入达到 198 亿美元，同比增长 56%。这其中，穆峰达和 Zepbound 仍是最核心的增长引擎。 穆峰达在 2026 年第一季度实现收入 86.62 亿美元，同比增长 125%。Zepbound 同期收入达到 41.60 亿美元，同比增长 80%。也就是说，仅这两个替尔泊肽相关品牌，一个季度合计收入就已经超过 128 亿

GEORGETOWN, Ky., May 28, 2026 /PRNewswire/ -- The ATTR Early-Career Research Forum, an academic colloquium focused on recognizing, inspiring, and equipping US-based physician-scientist fellows and junior faculty working in the field of ATTR amyloidosis, is back for its 3rd Annual installment, provided by Cornerstone Medical Education with sponsorship from AstraZeneca and Ionis Pharmaceuticals. Continue Reading Young investigators conducting active research projects in ATTR are encouraged to subm

Delix Therapeutics presented data for their novel neuroplastogen zalsupindole (DLX-001) at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference including NeuLogiq® Platform data which supports at-home administration in future trials BELFAST, Northern Ireland, May 28, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, was featured in

H1 helps healthcare players transform operations with AINEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- H1 recently received a $40M investment in a round led by CVS Health Ventures, the venture capital investment platform of CVS Health dedicated to driving health care innovation and digital disruption. The investment follows several successful projects that CVS Health and H1 have collaborated on, including a new AI model leading to a substantial improvement in health care provider directory accurac

Dr. Abhinav Sidana Brings Francis Medical's Minimally Invasive Prostate Procedure to Illinois CHICAGO, May 28, 2026 /PRNewswire/ -- Abhinav Sidana, MD, a urologic oncologist at the University of Chicago Medicine (UChicago Medicine), has performed the first commercial Vanquish® Water Vapor Ablation procedure in the Chicago metropolitan area, marking a significant milestone for patients in the region seeking minimally invasive prostate treatment options. The procedure was performed on an outpatien

MSAA's Multiple Sclerosis Implementation Network® (MSIN®) marks significant milestone to support improved care for people living with multiple sclerosis CHERRY HILL, N.J., May 28, 2026 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is proud to announce the expansion and important milestone of the Multiple Sclerosis Implementation Network® (MSIN®), enrolling more than 1,000 participants across 20 sites nationwide. MSIN is a patient-driven collaboration that connects MS ca

Findings to be presented at 2026 ASCO® Annual Meeting FORT MYERS, Fla., May 28, 2026 /PRNewswire/ -- Key findings from a study conducted with the participation of Florida Cancer Specialists & Research Institute, LLC (FCS) found comparable quality and safety outcomes across care delivery in accredited and non-FACT-accredited CAR T-cell therapy centers, with care location playing a key role in patient access and experience. Continue Reading Florida Cancer Specialists & Research Institute will pres

点击蓝字 关注我们 本 期 看 点 8月1日，正在成为医药行业一个很重要的时间节点。 随着医药代表备案、入院登记、院内拜访管理等要求进一步落地，过去很多药企熟悉的销售方式，都会被放到更透明、更可追溯的监管环境中。代表能不能进院、以什么身份进院、见了谁、讲了什么、是否合规留痕，都不再是企业内部自己说了算。 这意味着，药企过去那套以终端拜访、关系维护、费用推动和短期放量为核心的KPI体系，正在越来越难以持续。 对大型药企来说，真正的压力不是某一次监管检查，而是旧的增长引擎正在失灵：过去靠销售队伍密集覆盖、靠费用资源撬动终端、靠渠道关系完成放量的模式，已经无法支撑下一阶段发展。 就在这个时间窗口，齐鲁制药连续落子。 4月29日，齐鲁制药集团科学技术协会正式成立；近日，齐鲁制药又与人民健康达成战略合作，双方将围绕品牌建设、数智赋能、健康科普、基层医疗服务能力提升、公益活动等方向展开合作。 这两件事放在一起看，信号很清楚：齐鲁正在一边向内重建科技创新能力，一边向外重建健康传播和公众信任能力。 这也代表了头部药企必须面对的新课题：当旧销售不再好用，新的增长引擎必须建立在科技、合规、证据、科普和信任